目的 分析天津市第二人民医院2010—2013年肝病治疗口服中成药的临床用药情况，探讨用药90%（DU 90%）在肝病治疗口服中成药利用评价中应用的可行性和实用性，为临床用药的合理性和科学性提供参考。方法 收集、整理2010—2013年医院肝病治疗口服中成药用药频度（DDDs）和限定日费用（DDDc）进行统计，分析DU 90%部分药物的使用情况。结果 肝病治疗口服中成药的销售金额呈逐年上升趋势，增幅分别为21.70%、9.15%、26.43%；肝病治疗口服中成药的销售金额排名靠前的药物品种相对稳定，大多为清热解毒类、活血化瘀类和补益类药物；DU 90%部分药物的DDDs相对稳定，销售金额和DDDs的同步性较好。大部分药品的DDDc较低，构成比在2013年有所增加。结论 2010—2013年天津市第二人民医院肝病治疗口服中成药使用情况基本合理，DU 90%可以作为一种有效的工具，应用到处方的评价过程中。

Objective To analyze use of oral Chinese patent drugs for liver disease treatment in The Second People's Hospital of Tianjin during 2010—2013, and to discuss the feasibility and practicability of DU 90% in the evaluation of clinical drug utilization, so as to provide scientific evidence for the rational usage. Methods The utilization data including consumption sum, DDDs, and DDDc of oral Chinese patent drugs for liver disease treatments in The Second People's Hospital of Tianjin during 2010—2013 were analyzed statistically, and the use of DU 90% was analyzed. Results The consumption sum of oral Chinese patent drugs for liver disease treatment increased by 21.70%, 9.15%, and 26.43% from 2010 to 2013, and there was an upward trend. Drug varieties high ranking in the consumption sum were relatively stable, including antipyretic and antidote drugs, blood-activating, stasis-eliminating drugs and Qi-restoring drugs. DDDs of DU 90% drugs were relatively stable, and the sales sum and DDDs of synchronicity was better. DDDc of most drugs were low, and the composition ratio increased in 2013. Conclusion The use of oral Chinese patent drugs for liver disease treatment in The Second People's Hospital of Tianjin during 2010—2013 is basically reasonable, and DU 90% can be used as an effective tool, which is applied to the prescription of evaluation process.